Results 21 to 30 of about 586,330 (289)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports

Journal of Medical Case Reports, 2021
Background Fibrolamellar hepatocellular carcinoma is a unique tumor of the liver that differs from the classical hepatocellular carcinoma in diagnosis, behavior, and possibly treatment.
Ali AL Zahrani, Ali Alfakeeh
doaj   +1 more source

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. [PDF]

, 2011
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug combinations needed for personalized medicine.
Ashley, Carlee E, Brinker, C Jeffrey, Brown, Page A, Carnes, Eric C, Carroll, Nick J, Carter, Mark B, Chackerian, Bryce, Dunphy, Darren R, Durfee, Paul N, Evans, Deborah G, Hanna, Tracey N, Jiang, Xingmao, Liu, Juewen, Padilla, David, Parikh, Atul N, Peabody, David S, Petsev, Dimiter N, Phillips, Brandy, Phillips, Genevieve K, Wharton, Walker, Willman, Cheryl L   +20 more
core   +2 more sources

Risk prediction for dermatomyositis-associated hepatocellular carcinoma

BMC Bioinformatics, 2023
Objective To explore dermatomyositis signature genes as potential biomarkers of hepatocellular carcinoma and their associated molecular regulatory mechanisms.
Xusheng Zhang, Yongxin Ma, Kejun Liu, Long Chen, Lin Ding, Weihu Ma, Bendong Chen   +6 more
doaj   +1 more source

Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection [PDF]

, 2016
Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes. However, HCC surveillance remains costly, cumbersome and suboptimal. We tested whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance.
Ahn, Sang Hoon, Bird, Sheila M., Bird, Thomas G., Blunsum, Andrew, Cusack, Pearce, Dimitropoulou, Polyxeni, Hayes, Peter C., Hey, Shiying, Jenks, Sara J., Kelly, Sarah, Sturgeon, Catharine, Turner, Rebecca M.   +11 more
core   +4 more sources

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. [PDF]

, 2020
BackgroundTransforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib ...
Benhadji, Karim A, Cleverly, Ann, Estrem, Shawn T, Faivre, Sandrine, Gane, Ed, Giannelli, Gianluigi, Kelley, Robin K, Lahn, Michael M, Man, Michael, Paradis, Valerie, Raymond, Eric, Santoro, Armando, Smith, Claire, Wang, Shuaicheng   +13 more
core   +2 more sources

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

ZNF561 antisense RNA 1 contributes to angiogenesis in hepatocellular carcinoma through upregulation of platelet-derived growth Factor-D

Chinese Journal of Physiology, 2022
Hepatocellular carcinoma is a common malignant tumor with high recurrence rate. Long non-coding RNA (lncRNA) ZNF561 antisense RNA 1 (ZNF561-AS1) functions as an oncogenic lncRNA to promote the tumorigenesis of colorectal cancer. The role of ZNF561-AS1 in
Jihu Zheng, Zijian Guo, Zhanchao Wen, Huikang Chen   +3 more
doaj   +1 more source

Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. [PDF]

, 2018
Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68 co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a challenge.
Alves, Venancio Af, Cruise, Michael W, Ferrell, Linda, Gill, Ryan M, Graham, Rondell P, Greipp, Patricia T, Jain, Dhanpat, Jin, Long, Kakar, Sanjay, Kerr, Sarah E, Lam-Himlin, Dora, Longerich, Thomas, Nart, Deniz, Roberts, Lewis R, Roessler, Stephanie, Rustin, Jeanette G, Salaria, Safia N, Schirmacher, Peter, Solomon, David A, Sukov, William R, Terracciano, Luigi, Torbenson, Michael S, Wang, Xiaoke, Waterhouse, Emily, Yeh, Matthew M, Yilmaz, Funda, Zaid, Nida, Zreik, Riyam T   +27 more
core   +1 more source

Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma [PDF]

, 2007
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of patients with hepatocellular carcinoma (HCC). Methods: We stratified a cohort of 278 HCC patients using six independent predictors of survival according ...
Angelika Schrader, Bloomston M, Bosch FX, Burkhard Göke, Castells A, Christian Graeb, Christoph Jüngst, Curley SA, Dieter Jüngst, Florian Löhe, Franco D, Goldberg SN, Gundula Straub, Horst-Günter Rau, Karl-Walter Jauch, Kotoh K, Livraghi T, Livraghi T, Livraghi T, Maximilian Reiser, Qian J, Ralf-Thorsten Hoffmann, Rolf Schauer, Rossi S, Rossi S, Ryder SD, Sasaki Y, Selin Dogan, Takenaka K, Thomas Helmberger, Tobias Jakobs, Tobias Waggershauser, Wolfgang H. Caselmann   +32 more
core   +1 more source

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE) : study protocol for a randomized controlled trial [PDF]

, 2012
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such ...
Al Younis, Imad, Coenraad, Minneke J, Defreyne, Luc, Lam, Marnix GEH, Lambert, Bieke, Seinstra, Beatrijs A, van den Bosch, Maurice AAJ, van Erkel, Arian R, van Erpecum, Karel J, van Hoek, Bart, Van Vlierberghe, Hans, Verkooijen, Helena M   +11 more
core   +1 more source